
Germany's Psychiatric Blind Spot: Behind Prison Walls
In this interview with Coliquio , a Medscape Network platform, Gregor Gross, MD, from the psychiatric department at Straubing Prison in Straubing, Germany, discussed the challenges and insights of providing psychiatric care within the German prison system. As a specialist in psychiatry and psychotherapy, Gross offered candid insights into working at the intersection of acute mental health crises, systemic understaffing, and occasional moments of unexpected therapeutic success. It's a conversation about caring for society's most marginalized individuals — and what can happen when their psychiatric illnesses are overlooked.
Why is a dedicated psychiatric unit necessary in prisons?
Mental health disorders are significantly more prevalent among inmates than in the general population. Nearly half of all prisoners struggle with substance abuse. Approximately 25% of male inmates suffer from depression, and among female inmates, the rate is about 33%. Psychotic disorders are present in roughly 4% of the prison population, and ADHD is also relatively common, affecting about 10%. At Straubing Prison, around half of the inmates are under continuous psychiatric care, which is not an exception.
Does incarceration itself trigger these mental health issues?
Most inmates enter prison with preexisting mental health conditions; many have been incarcerated multiple times and are familiar with the environment, which reduces stress. However, first-time inmates often develop adjustment disorders, typically manifesting as temporary depressive reactions. These usually subside after a few weeks or months. In general, the prison environment rarely causes severe psychiatric problems on its own.
Are there specific groups of inmates who are particularly vulnerable?
Yes, especially those serving substitute custodial sentences. These individuals have committed minor offenses, such as shoplifting or fare evasion, and are unable to pay fines due to psychiatric or social issues, leading to incarceration. Repeated imprisonment exacerbates their underlying problems rather than resolving them.
Does the justice system inadvertently create its own inmates?
Unfortunately, yes. A revolving-door effect occurs where individuals are released only to return shortly after for similar minor offenses they cannot afford to rectify financially. The root causes of their behavior are never addressed, indicating a clear need for political intervention.
The suicide rate in prisons is reportedly high. How is this managed?
At Straubing, we conduct systematic, scientifically validated suicide screenings upon intake and during high-risk situations, such as post-sentencing or pre-release. These periods often induce anxiety about the future, posing real suicide risks.
What measures are taken if someone is at high risk?
Immediate, intensive psychiatric care is provided. Often, this support is sufficient to navigate the crisis. We also have cells equipped with camera surveillance, and some inmates request placement there due to fear of impulsive actions. Coercive measures are rare and used only when there's an acute suicide risk, which may include removing clothing to prevent self-harm, substituting with paper garments. Despite precautions, the prison suicide rate remains 10 times higher than in the general population. Therefore, peer-support programs, like the model project in Munich where trained inmates assist newcomers, are vital and should be expanded.
How adequate is psychiatric care in German prisons overall?
Frankly, it's significantly below what's necessary. Despite the high number of mentally ill inmates, many facilities lack psychiatric services. Nationwide, there are only about 30 prison psychiatrists for approximately 60,000 inmates, equating to over 1000 cases per doctor. Many positions remain unfilled due to a shortage of qualified professionals. Consequently, prison medical staff without psychiatric training often have to fill the gap, which is far from ideal.
Would transferring mentally ill inmates to regular hospitals be beneficial?
In theory, yes, but it's rarely feasible in practice. Many hospitals refuse inmates due to capacity issues or stigma, perceiving their symptoms as criminal behavior rather than illness. Additionally, the presence of correctional officers disrupts hospital routines, leading to infrequent acceptance of such transfers.
How can more psychiatrists be attracted to work in prisons?
A major issue is the lack of exposure to prison psychiatry during medical education and specialist training. Yet, it's an incredibly engaging field. If medical students and residents experienced this work firsthand, they would appreciate its professional and human relevance, potentially increasing interest in this specialty.
What other steps are being taken to address the care deficit?
The German Society for Psychiatry and Psychotherapy, Psychosomatics, and Neurology has established a working group to assess the actual needs for psychiatric care in prisons. The goal is to obtain reliable data to accurately determine the extent of the deficit, which is essential for advocating political improvements. The principle of equivalence dictates that medical care in prisons must be comparable to that outside; incarceration should not result in inferior healthcare, especially psychiatric services.
Can telemedicine help alleviate the problem?
In some German federal states, telepsychiatry is well established in prisons. However, it's intended as a supplement, not a replacement. Effective psychiatric treatment requires personal contact and a cohesive team, including on-site nurses and therapists, which cannot be fully replicated through video consultations.
Are there inmates who particularly benefit from prison psychiatric services?
Yes, notably individuals with migration backgrounds. Many lacked access to psychiatric care in their home countries or in Germany due to inadequate healthcare systems or language barriers. In prison, we can often diagnose conditions like depression, psychosis, or ADHD for the first time, offering opportunities they might never have received otherwise.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
an hour ago
- Medscape
Infographic: What's Happening With PAs' Paychecks
Physician assistant (PA) compensation in the US on average rose by about 5% in 2024, to $149,000 from $142,000 a year earlier. Bigger bonuses and incentive payments were more responsible than were salary hikes. Still, the PA profession is wrestling with a gender pay gap, as a male PA on average reported about $161,000 in compensation vs $143,000 for a female counterpart, according to a new Medscape report. This infographic presents key findings from a new report on how much PAs are earning around the country. To learn more, check out the Medscape Physician Assistant Compensation Report 2025. Medscape Physician Assistant Compensation Report 2025


Medscape
3 hours ago
- Medscape
RCGP Urges Support to Save Declining GP Partnership Model
The Royal College of General Practitioners (RCGP) has warned that GP partnerships are under threat, as the number of partners in England has dropped by 25% over the past decade. In a new report, the college urged action to 'break down barriers to partnership' and called for modernisation of the model to make it more attractive to younger doctors. While the RCGP reaffirmed its support for the independent contractor model, it said there was 'room for modernisation and innovation', and backed ' a mixed economy' of contractual models to deliver general practice. Shift in Workforce Between 2015 and 2025, the number of GP partners in England fell from 24,491 to 18,367. Over the same period, the number of salaried GPs rose by 81%, from 10,270 in September 2015 to 18,557 in December 2024. As of June 2024, GP partners were a minority among fully qualified GPs for the first time. The most significant drop in partnership was seen in younger doctors. Among GPs aged 30-34, numbers fell by 72.9%. The only age group to show growth was those aged 60-64, up by 19.5%. Barriers to Partnership Rising workload, administrative burdens, and concerns about financial risk were cited as major deterrents to partnership. Professor Kamila Hawthorne, RCGP chair, said that many GPs were discouraged by the unlimited personal liability that comes with being a partner. She also pointed to the responsibilities of owning or leasing premises and managing staff, especially as patient demand increases. Exploring Alternatives The RCGP report explored alternative business models that could support general practice, including limited companies, limited liability partnerships (LLPs), and community benefit societies. The college maintained that partnerships still offered flexibility and potential for innovation, particularly if financial and workload pressures could be reduced. In 2024, more than half (55%) of RCGP members said they would be more likely to consider partnership if financial risks were lower. A review by Lord Darzi highlighted the financial discipline of GP partnerships, noting that they could not run large deficits like other parts of the NHS. Earlier this year, the Nuffield Trust described the current GP partnership model as 'withering'. The health think tank warned that the government's plans to improve GP access were at risk due to the fall in partner numbers. Thea Stein, chief executive of the Nuffield Trust, told Medscape News UK : 'It is hard to see partnership being the dominant model in the future.' She called for support where the model works well, but said new models must also be explored. Hawthorne maintained that 'there are elements of the traditional GP partnership that can be improved and modernised, while retaining its core strengths'. The GP partnership model has huge benefits for the NHS and for patients, she added. Government Response A Department of Health and Social Care (DHSC) spokesperson acknowledged the strengths of the partnership model, including efficiency, innovation, and continuity of care. 'However, we also recognise that this is not the only model delivering general practice,' the spokesperson told Medscape News UK . 'GP practices can choose to organise themselves in different ways and also provide good outcomes in terms of staff engagement and patient experience.'


Associated Press
3 hours ago
- Associated Press
Hematologists Set the Stage for Market Disruption as Next-Gen Hemophilia Therapies Gain Traction
EXTON, PA, June 12, 2025 (GLOBE NEWSWIRE) -- As the hemophilia landscape continues to transform, new research from Spherix Global Insights reveals a market on the cusp of significant evolution driven by innovation, physician receptivity, and an increasingly nuanced approach to patient care. The latest Market Dynamix™: Hemophilia (EU) 2025 report, based on feedback from 160 hematologists across the UK, France, Germany, Italy, and Spain, illuminates shifting treatment preferences and the widening role for advanced therapeutic options across hemophilia A and B. The study captures a broadening treatment mindset in a market historically dominated by factor replacement therapies. Although conventional agents have provided stability for many patients, Spherix data highlight an increasingly urgent unmet need, particularly among patients with inhibitors. In fact, patients with inhibitors represent the group for whom hematologists see the greatest opportunity for innovation. Products such as Alhemo (Novo Nordisk) and Qfitlia (Sanofi) are already entering the physician consciousness as promising options, with early prescribing experiences for Alhemo in Germany showing favorable clinical feedback. Importantly, European hematologists are signaling readiness to embrace novel mechanisms that deliver sustained efficacy and reduce treatment burden. Beyond Alhemo and Hympavzi, there is rising anticipation for agents like Qfitlia and Mim8 (Novo Nordisk). Gene therapy, once seen as aspirational, is becoming a more realistic consideration, especially in hemophilia B where therapeutic alternatives remain limited. CSL Behring's Hemgenix and BioMarin's Roctavian are drawing interest, albeit tempered by concerns around cost and long-term outcomes. Spherix data reveal a market increasingly driven not just by efficacy but by lifestyle alignment and convenience. This reflects a maturation of brand expectations, where baseline efficacy is presumed and differentiation hinges on quality-of-life enhancements. The move away from standard half-life (SHL) and even extended half-life (EHL) products is evident, particularly in hemophilia A, where agents like Hemlibra (Roche/Genentech) and Altuvoct/Altuviiio (Sanofi) are rapidly becoming standard practice. Underlying these trends is a broader shift in therapeutic philosophy: goals focus less and less on symptom control (which is assumed) while disease modification becomes centrally important, mirroring changes seen in other chronic specialty markets. Hematologists are prepared to make transitions, especially when options can seamlessly accommodate inhibitor development without requiring treatment change. For Hympavzi, Alhemo, and Qfitlia, upcoming Launch DynamixTM tracking among US hematologists (available June 13th) underlines similar themes, with projected prescribing steadily rising for these novel agents. Additional metrics included in launch tracking include impact of product features and manufacturer programs on prescribing, assessment of likely patient groups for initial product trialing, and perspectives on which brand(s) are likely displaced by newer market entrants. Ultimately, as the treatment paradigm continues to evolve, biopharma stakeholders seeking success in the hemophilia space will need to align not only with clinical outcomes but also with patient-centric attributes now prioritized in physician decision-making. Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents. Launch Dynamix™ is an independent service providing monthly benchmarking of newly launched products for the first eighteen months of commercial availability, augmented by a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand. About Spherix Global Insights Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community. As a trusted advisor and industry thought leader, Spherix's unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth. To learn more about Spherix Global Insights, visit or connect through LinkedIn. For more details on Spherix's primary market research reports and interactive dashboard offerings, visit or register here: NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight's analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release. Sarah Hendry, Hematology Franchise Head Spherix Global Insights 4848794284 [email protected]